The combined company will have nine products with more than $1 billion in annual sales and significant potential for growth in oncology, immunology and inflammation and cardiovascular disease.
— Read on www.cnbc.com/2019/01/03/bristol-myers-to-buy-celgene-in-a-74-billion-deal.html
![You are currently viewing Bristol-Myers to buy Celgene in a $74 billion deal](https://medcontrolling.com/wp-content/uploads/2019/01/e030b60e2de91c72d252440dee4a5b97e673e4d318b0144395_640_Deal.jpg)